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Introduction: The severity of joint damage progression in rheumatoid arthritis (RA) is heritable. Several genetic
variants have been identified, but together explain only part of the total genetic effect. Variants in Interleukin-6 (IL-6),
Interleukin-10 (IL-10), C5-TRAF1, and Fc-receptor-like-3 (FCRL3) have been described to associate with radiographic
progression, but results of different studies were incongruent. We aimed to clarify associations of these variants
with radiographic progression by evaluating six independent cohorts.
Methods: In total 5,895 sets of radiographs of 2,493 RA-patients included in six different independent datasets from
the Netherlands, Sweden, Spain and North-America were studied in relation to rs1800795 (IL-6), rs1800896 (IL-10),
rs2900180 (C5-TRAF1) and rs7528684 (FCRL3). Associations were tested in the total RA-populations and in anti-citrullinated
peptide antibodies (ACPA)-positive and ACPA-negative subgroups per cohort, followed by meta-analyses. Furthermore,
the associated region C5-TRAF1 was fine-mapped in the ACPA-negative Dutch RA-patients.
Results: No associations were found for rs1800795 (IL-6), rs1800896 (IL-10) and rs7528684 (FCRL3) in the total
RA-population and after stratification for ACPA. Rs2900180 in C5-TRAF1 was associated with radiographic progression
in the ACPA-negative population (P-value meta-analysis = 5.85 × 10−7); the minor allele was associated with more
radiographic progression. Fine-mapping revealed a region of 66Kb that was associated; the lowest P-value was for
rs7021880 in TRAF1. The P-value for rs7021880 in meta-analysis was 6.35 × 10−8. Previous studies indicate that the region
of rs7021880 was associated with RNA expression of TRAF1 and C5.
Conclusion: Variants in IL-6, IL-10 and FCRL3 were not associated with radiographic progression. Rs2900180 in C5-TRAF1
and linked variants in a 66Kb region were associated with radiographic progression in ACPA-negative RA.Introduction
Thanks to the introduction of novel treatments and up-to-
date treatment strategies, the severity of joint destruction in
rheumatoid arthritis (RA) has decreased considerably [1].
Nonetheless, in daily clinical practice radiographic progres-
sion is still prevalent and understanding the mechanisms
underlying the inter-individual differences in radiographic
progression is relevant. The heritability of joint destruction
has been estimated to be 45% to 58% [2]. Thus far, several
genetic risk factors for radiographic progression have been
replicated in independent studies or found significant in* Correspondence: H.W.van_Steenbergen@lumc.nl
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article, unless otherwise stated.meta-analyses of different cohorts, but together explain
only 18% of variance in radiographic progression [3].
Part of the ‘missing heritability’ might be explained by
not yet identified common genetic variants that associate
with radiographic progression in RA. The literature on
genetic variants for radiographic progression was reviewed
recently [4]. Published and yet unpublished data were
combined, and it was concluded that for 12 genetic vari-
ants their associations with radiographic progression were
either replicated in independent cohort studies or found
significant in meta-analysis of multiple cohorts. However,
the associations between rs1800795 in Interleukin (IL)-6,
rs1800896 in IL-10, rs2900180 in C5-TRAF1 and rs7528684
in Fc-receptor-like-3 (FCRL3) and joint damage were not
clear [4].d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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joint damage at baseline in 964 United Kingdom (UK)
RA patients, but the association was mainly observed in
autoantibody-positive patients [5]. IL-10 was observed as
a severity factor evaluating 138 RA patients [6], but not
in a study of 108 RA patients [7]. Rs2900180 in C5-
TRAF1 was identified in a cross-sectional study [8]; it
was also found significant in another UK cohort [9], but
not in other datasets [4]. Rs7528684 in FCRL3 was ob-
served as a severity factor in two studies [10,11], although
the association was once restricted to the subgroup with a
disease duration of at least 10 years [11] and not found in
other datasets [4,12].
Presumably, the scarcity of large well-defined longitudinal
cohorts of RA patients who were treated in eras when early,
tailored treatment and use of biologics were uncommon
may have contributed to the incongruent findings.
In order to increase the comprehension on the associa-
tions of these variants with radiographic progression in RA
and in the anti-citrullinated peptide antibodies (ACPA)-
positive and ACPA-negative subgroups, we performed the
present study and evaluated these genetic variants in six
independent European and North American RA cohorts in
one of the largest studies to date on RA severity.
Methods
Study population
The six cohorts consisted in total of 5,895 sets of
radiographs of 2,493 RA patients who fulfilled the 1987
American College of Rheumatology (ACR) criteria (Table 1).Table 1 Patient characteristics
Leiden EAC Ume
Total number of patients 597 459
Total number of sets of radiographs 3,143 868
Radiographic follow-up in yearsa 7 2
Disease duration in years at radiograph, mean (SD)b NA NA
Method of scoring SHS Larse
Year of diagnosis 1993-2006 1995
Female, number (%) 402 (67.3) 321
Age at diagnosis in years, mean (SD) 57.1 (15.6) 53.9
ACPA-positive, number (%) 309 (52.8)c 339
MAF rs1800795 (G) (IL-6), % 42.0 46.5
MAF rs1800896 (T) (IL-10), % 48.1 44.3
MAF rs2900180 (A) (C5-TRAF1), % 36.0 36.4
MAF rs3761959 (A) (FCRL3), %g 45.5 44.2
aFor the studies with longitudinal radiographic data (more than one radiograph in t
studies with one radiograph per patient, the mean disease duration at time of the r
EAC cohort; dACPA status missing in 48 patients from the HCSC-RAC cohort; eACPA
not available in the NARAC; data on a proxy rs1554606 (R2 = 0.868) were available;
rs3761959 (R2 = 1.000) were available. ACPA, anti-citrullinated peptide antibodies; EA
Arthritis Cohort; MAF, minor allele frequency; NA, not applicable; NARAC, North Am
Diseases; SD, standard deviation; SHS, Sharp-van der Heijde score.All patients gave their informed consent and approval was
obtained from the local Ethical Committee of each hospital
(METC Leiden University Medical Center, EPN University
Hospital Umeå, San Carlos Clinical Hospital Ethics Com-
mittee, Via Christi IRB and North Shore-LIJ Health System
IRB).
Leiden Early Arthritis Clinic (EAC)
This cohort contained 597 Dutch early RA patients
included between 1993 and 2006 [13]. At baseline and
during yearly follow-up visits over seven years, 3,143
sets of hand and feet radiographs were made and
chronologically scored by one experienced reader ac-
cording to the Sharp-van der Heijde method (SHS)
(within reader intraclass correlation coefficients (ICC)
0.91). The initial treatment strategy differed for differ-
ent inclusion periods: patients included in 1993 to 1995
were initially treated with non-steroidal anti-inflammatory
drugs (NSAIDs), patients included in 1996 to 1998 were
initially treated with hydroxychloroquine or sulfasalazine
and patients included in 1999 to 2006 were promptly
treated with methotrexate [13].
Umeå
This cohort involved 459 Swedish early RA patients
included between 1995 and 2010. At baseline and after
two years in total, 868 radiographs of hands and feet were
made and scored using the Larsen score by two trained
readers as described previously [14]. Treatment strategies
differed between 1995 and 2000, 2000 and 2005 and 2006å HCSC-RAC Wichita NDB NARAC Total
383 101 568 385 2,493
573 358 568 385 5,895
10 15 NA NA
NA NA 10.1 (5.1) 13.9 (10.5)
n SHS SHS SHS SHS
-2010 1976-2011 1963-1999 1980-1999 1953-2002
(69.9) 293 (76.5) 70 (69.3) 444 (78.2) 281 (73.0)
(14.5) 47.0 (14.0) 49.0 (11.7) 48.6 (12.7) 40.8 (11.9)
(73.9) 165 (49.3)d 97 (96.0)e 453 (79.8) 385 (100)
33.8 46.5 40.8 42.1f
52.7 49.0 48.5 45.6
27.8 36.6 35.6 39.0
42.2 50.0 49.7 47.4
ime), the maximum radiographic follow-up duration was reported; bfor the
adiograph was reported; cACPA status missing in 12 patients from the Leiden
status missing in one patient from the Wichita cohort; fData on rs1800795 were
gin all cohorts data on rs7528684 were not available; data on a perfect proxy
C, Early Arthritis Clinic; HCSC-RAC, Hospital Clinico San Carlos – Rheumatoid
erican Rheumatoid Arthritis Consortium; NDB, National Data Bank for Rheumatic
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in the subsequent treatment periods.
Hospital Clinico San Carlos – rheumatoid arthritis cohort
(HCSC-RAC)
This Spanish cohort comprised 383 early RA patients, diag-
nosed between 1976 and 2011 [15]. During the first 10 years
after disease-onset 573 radiographs of hands were made and
scored chronologically according to the SHS (ICC 0.99).
Initial treatment strategies differed for different inclusion pe-
riods: <1990 (initial treatment with NSAIDs), 1990 to 1999
(initial monotherapy conventional disease-modifying anti-
rheumatic drugs (DMARDs), 2000 to 2004 (initial mono-
therapy regularly and combination therapy rarely), 2005 to
2009 (initial combination therapy regularly used as well as
biologics) and 2010 to 2011 (tailored treatment).
Wichita
This cohort comprised 101 patients from one practice in
Wichita (KS, US) diagnosed between 1963 and 1999
[16]. In total, 358 sets of hand radiographs were made
during the first 15 years after disease onset and scored
with known time-order using the SHS (ICC 0.98).
National data bank for rheumatic diseases (NDB)
This dataset included 568 patients from the US and
Canada, who were diagnosed between 1980 and 1999
[17]. One radiograph set of the hands was available per
patient and SHS-scored (ICC 0.98).
North American Rheumatoid Arthritis Consortium (NARAC)
This dataset comprised 385 unrelated RA patients, who
were diagnosed between 1953 and 2002 [18]. One radio-
graph set of the hands was available per patient. The ra-
diographs were SHS-scored (ICC 0.99). The patients in
the three North American cohorts developed RA in eras
when early, tailored treatment and use of biologics were
uncommon; no treatment effects were observed for
different era of diagnoses.
Genotyping
In the EAC, Umeå, HCSC-RAC, Wichita and NDB co-
horts genotyping was done using the Immunochip accord-
ing to Illumina’s protocols as described previously [19,20].
In the NARAC genotyping was performed using the
Illumina Hapmap 500 BeadChip as described elsewhere
[18]. Genotyping data were extracted of rs1800795 in
IL-6, rs1800896 in IL-10, rs2900180 in C5-TRAF1 and
rs7528684 in FCRL3. Data on rs1800795 were not avail-
able in the NARAC but genotyping data of a proxy
rs1554606 (R2 = 0.868 and D’ = 0.932) were retrieved. In
all cohorts, data on rs7528684 (FCRL3) were not available;
data on a perfect proxy rs3761959 (R2 and D’ both 1.000)
were studied.Fine-mapping
The C5-TRAF1 region was fine-mapped in ACPA-negative
patients of the EAC. Data of genetic variants in the region
of rs2900180 were retrieved using the Immunochip,
starting at the upstream haplotype block of PHF19 until
the downstream haplotype block of C5 (chromosome 9:
122,680 Kb to 122,927 Kb). Genotypic data were accepted
after quality control as described elsewhere [20], requiring
minor allele frequency (MAF) >0.0001, Hardy-Weinberg
equilibrium (HWE) P >0.001 and genotyping success
rate >0.99. Genetic outliers and relatives (both defined by
principal component analysis) and patients with a gender
mismatch between the data file and DNA were excluded.
In this way, 424 SNPs were obtained and analyzed for
their association with radiographic progression. The vari-
ant with the strongest association was subsequently associ-
ated with radiographic progression in the ACPA-negative
patients of the Umeå, HCSC-RAC and NDB cohorts.
Downstream effect
To identify functional downstream effects of C5-TRAF1, a
search was performed in publically available databases
and datasets [21-26]. Explored were the RegulomeDB [21],
datasets that have evaluated constitutive RNA expression
by mapping expression quantitative trait locus (eQTL) in
peripheral blood samples from 8,086 individuals [22] and
purified CD4+ T-cells and monocytes from 461 individuals
[23], and datasets that have evaluated response eQTLs
(QTLs associated with change in expression after stimula-
tion) on lymphoblastoid cell lines from 40 individuals [24],
monocytes from 432 individuals [25] and monocytes
derived dendritic cells from 534 individuals [26].
Statistical analysis
Associations between genotypes and radiographic joint
damage were analyzed per cohort using an additive model.
In all datasets, radiographic scores were log-transformed
(log10(radiographic score +1)) to approximate a normal
distribution. The residuals of the used models were
normally distributed around the zero-line in all cohorts,
indicating a good fit of the models (Additional file 1).
In the cohorts with multiple sets of radiographs over
time (EAC, Umeå, HCSC-RAC and Wichita) a multi-
variate normal regression model for longitudinal data
was used with radiographic scores as response variable.
This method takes advantage of the within-person cor-
relation between repeated measurements; as such, the
radiographic progression rates were estimated more pre-
cisely in the cohorts with serial radiographs compared to
datasets with one radiograph per patient (for a detailed
description see reference [27]). The obtained effect size
(beta) was back-transformed to the normal score and
indicated the fold rate of joint destruction per year per
minor allele compared to the reference genotype.
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(NDB and NARAC) the estimated yearly progression rate
was calculated (total SHS divided by number of disease year
at the time of the radiograph) in order to make the
estimates of the progression rates comparable to those in
the other datasets. A linear regression analysis was used
with estimated yearly progression as outcome variable.
Here, also, the obtained effect size was back-transformed
and indicated the fold rate of joint destruction per year per
minor allele compared to the reference common genotype.
In all datasets, adjustments were made for age and gen-
der. In the cohorts that included patients in periods with
different treatment strategies (EAC, Umeå and HCSC-
RAC) analyses were also adjusted for the inclusion period
as proxies for differences in treatment strategies.
The majority of datasets studied were estimated to be
insufficiently powered to find statistically significant as-
sociations in the individual cohorts. Therefore, the effect
sizes and standard errors of the individual analyses were
combined in an inverse-weighted variance meta-analysis
to test the overall association. This was allowed because
the obtained effect sizes of the individual datasets, al-
though different methods were used to score joint de-
struction (SHS and Larsen), all represented the relative
increase (without units) of progression in joint destruc-
tion per year. The meta-analysis weights the results with
a low standard error stronger than the results with a
high standard error, preventing an overrepresentation of
less precise data on the outcome. Subsequently, datasets
with smaller 95% confidence intervals (CI) had a larger
weight in the meta-analysis.
The cut-off for statistical significance was set at P <4.17 ×
10−3 using the Bonferroni correction (four variants tested
in the total RA population and ACPA-positive and ACPA-
negative subgroups: 0.05/12 tests = 4.17 × 10−3). For the
fine-mapping analyses the cut-off for statistical significance
was set at P <1.18 × 10−4, also using the Bonferroni cor-
rection (0.05/424 tests = 1.18 × 10−4). Analyses were per-
formed using IBM SPSS version 20 and Stata version 12.0.
Results
Patient characteristics and analyses on total
RA-population
The minor allele frequencies for rs1800795 (G) in IL-6,
rs1800896 (T) in IL-10, rs2900180 (A) in C5-TRAF1 and
s3761959 (A) (=perfect proxy rs7528684 (G) in FCRL3 in
the different cohorts are presented in Table 1. First, ana-
lyses were done on the total RA-population. Statistical sig-
nificance was obtained in none of the individual cohorts.
The directionality of the effects was variable across the
cohorts (Figure 1). Also in the meta-analyses on the six co-
horts (2,493 patients and 5,895 sets of radiographs in total)
no significant associations were obtained for rs1800795 in
IL-6 (fixed effects model P = 0.72), rs1800896 in IL-10(fixed effects model P = 0.93), rs2900180 in C5-TRAF1
(fixed effects model P = 0.22) and rs7528684 in FCRL3
(fixed effects model P = 0.83).
Analyses of ACPA-positive and ACPA-negative rheumatoid
arthritis
As some of the initial reports on these four genetic variants
stratified or adjusted the analyses for the presence of ACPA
and as ACPA-positive and ACPA-negative RA are consid-
ered as separate disease entities, analyses were performed
on radiographic progression in ACPA-positive and ACPA-
negative RA separately. The ACPA-positive subgroup com-
prised 1,748 patients (with 3,820 sets of radiographs) who
were included in six cohorts. The ACPA-negative subgroup
included 681 patients (with 1,933 sets of radiographs) who
were included in the EAC, Umeå, HCSC-RAC and NDB
cohorts (Table 1).
Rs1800795 (IL-6), rs1800896 (IL-10), and rs7528684
(FCRL3) were not associated with radiographic progression,
neither in the ACPA-positive nor in the ACPA-negative
group of RA-patients (Additional file 2). Rs2900180 in C5-
TRAF1 was not associated with radiographic progression
in ACPA-positive RA (Additional file 2). In contrast, in
ACPA-negative RA a significant association with radio-
graphic progression was observed in the EAC (P = 2.88 ×
10−5) (Figure 2A). The directionality of the effect was simi-
lar in the Umeå, HCSC-RAC and NDB cohorts. Also, the
meta-analysis revealed a significant association (fixed ef-
fects model P = 5.85 × 10−7) (Figure 2B). In all cohorts,
patients with the minor allele had a higher rate of joint
destruction. For instance, RA patients included in the
EAC with one minor allele had a 1.045 fold rate of joint
destruction per year compared to patients with the com-
mon genotype; this equals a 36% (1.045^7) higher rate of
joint destruction over seven years (Figure 2A).
Fine-mapping
To examine if other genetic variants within the C5-
TRAF1 region had statistically stronger associations with
the rate of joint destruction than rs2900180, this region
was fine-mapped in the ACPA-negative EAC patients. In
total, 43 variants had a P-value below the threshold for
multiple correction (P <1.18 × 10−4) of which 34 were
statistically more strongly associated with radiographic
progression than rs2900180 (Figure 3, Additional file 3).
The 43 associating variants, including rs2900180, were
all located within a 66 Kb region spanning TRAF1 and
extending downstream to the C5-TRAF1 intergenic re-
gion and upstream to the TRAF1-PHF19 intergenic re-
gion. The variant with the lowest P-value was rs7021880
located in TRAF1 (beta = 1.052 per year per minor allele,
P = 1.39 × 10−6). In a conditional analysis on rs2900180
and rs7021880 (R2 = 0.864), both variants lost statistical
significance (rs2900180 beta = 0.99 P = 0.77; rs7021880
Figure 1 (See legend on next page.)
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Figure 1 Genetic variants in IL-6 (A), IL-10 (B), C5-TRAF1 (C) and FCRL3 (D) in relation to radiographic joint damage progression. Presented
are the yearly radiographic progression rates per individual cohort and the meta-analyses evaluating the six cohorts combined, consisting in total of
2,493 patients and 5,895 sets of radiographs. None of the studied genetic variants were significantly associated with radiographic progression, neither
in the individual cohorts nor in meta-analysis. Rs1800795 (IL-6) I2 0.0%, P 0.67; P fixed effect 0.72, P random effect 0.72; rs1800896 (IL-10) I2 20.8%, P 0.28;
P fixed effect 0.93, P random effect 0.89; rs2900180 (C5-TRAF1) I2 28.7%, P 0.22; P fixed effect 0.22, P random effect 0.63; rs7528684 (FCRL3) I2 26.0%,
P 0.24; P fixed effect 0.83, P random effect 0.73.
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ants reflected one signal, although it is noteworthy that
the effect size of rs2900180 was reduced to 0.99 and the
effect size of rs7021880 increased slightly. Additionally,
the fine-mapping analyses were performed when condi-
tioning on the strongest associating variant rs7021880. No
variants were statistically significant associated with radio-
graphic progression independent of rs7021880 (Additional
file 4). In meta-analysis of the ACPA-negative patients of
the EAC, Umeå, HCSC-RAC and NDB cohorts rs7021880
was significantly associated with radiographic progression
(P fixed effects model = 6.35 × 10−8) (Additional file 5).
Downstream effect
To identify functional downstream effects of the region of
rs7021880, a database and literature search of transcriptionFigure 2 Rs2900180 in C5-TRAF1 in relation to radiographic progression
during seven years of follow-up of ACPA-negative RA patients with different g
rate of joint destruction per year compared to patients with the common gen
individual cohort and the meta-analysis evaluating the cohorts with ACPA-ne
cohort was not performed as it included only three ACPA-negative patients. Istudies was performed. The RegulomeDB indicated that
this locus has multiple signs of transcriptional activity [21].
Based on RNA expression evaluated by eQTL mapping of
peripheral blood samples of 8,086 individuals [22], the
minor allele of rs7021880 was negatively correlated with
RNA expression of different genes in this region (cis-
eQTL), with the lowest P-value for the expression of
TRAF1 (P = 4.93 × 10−35) (Additional file 6). However, the
strongest correlation between variants in this region with
TRAF1 expression was observed for rs2416804 in TRAF1
(D’ = 1.000, R2 = 0.668 with rs7021880). A study evaluating
CD4+ T-cells and monocytes of 461 individuals observed
that several variants in the region of rs7021880 had cis-
eQTL effects on TRAF1 (in T-cells) and on C5 (in mono-
cytes) [23]. Both studies explored constitutive expression
[22,23]. The effect of a regulatory variant on genein ACPA-negative RA patients. (A) Depicted are the median SHSs
enotypes in the Leiden EAC. Patients had per minor allele a 1.045 fold
otype (P = 2.88 × 10−5). (B) Yearly radiographic progression rates per
gative patients. Analysis of the ACPA-negative subgroup of the Wichita
2 33.0%, P = 0.22; P fixed effect = 5.85 × 10−7, P random effect = 0.0024.
Figure 3 (See legend on next page.)
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Figure 3 LD plots of the C5-TRAF1 region. (A) Total region in hapmap CEU patients and (B) fine-mapped in Leiden EAC. The colors reflect de D’
between the SNPs. Coordinates relate to NCBI36 hg18 release 2006. (C) Results of the multivariate normal regression analysis for 424 variants in the
C5-TRAF1 region in the ACPA-negative patients of the EAC. Rs2900180 is the initially studied variant (green), rs7021880 is the variant with the lowest
P-value (red) and rs10818488 is the variant we previously studied in relation to radiographic progression (yellow) and did not associate with
radiographic progression in the total population [29]. Also in the current study, rs10818488 did not pass the cut-off for multiple testing correction in
the ACPA-negative patients. Using the Bonferroni correction (considering 424 variants studied) the cut-off for statistical significance was set at
1.18 × 10−4 as represented by the horizontal line. ACPA, anti-citrullinated peptide antibodies; EAC, Early Arthritis Clinic; LD, linkage disequilibrium.
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tain stimuli. Response eQTLs have been studied in different
cell types using different stimuli [24-26]. In lymphoblast cell
lines of 40 Asian individuals variants in the C5-TRAF1 re-
gion were associated with TRAF1 expression after phorbol
myristate actetate (PMA) stimulation, but not with C5 ex-
pression [24]. Monocytes are cardinal innate immune cells
that upon stimulation, exhibit large scale gene transcription
and cytokine production. A recent study in 432 individuals
showed that the expression of TRAF1 and C5 significantly
changed in monocytes after stimulation with lipopolysac-
charide (LPS) [25]. Furthermore, rs7021880, associated with
radiographic progression in our study, as well as several
other variants in this region, affected gene expression after
two hours of LPS stimulation; a strong cis-effect was seen
for expression of TRAF1 (P for rs7021880 = 1.20 × 10−6,
t-stat = −5.00) (Additional file 7) [25]. Similarly, in a com-
parable study of stimulation-specific eQTLs in dendritic
cells derived from peripheral blood monocytes of 534 in-
dividuals, the RA-susceptible variant rs881375 in the inter-
genic TRAF1-PHF19 region (R2 = 0.902, D’ = 1.000 with
rs7021880) showed response eQTL after LPS and influenza
stimulation (respectively P = 6.33 × 10−8 and 1.04 × 10−10)
[26]. Together these data indicate a response eQTL effect
on monocytes and dendritic cells derived from monocytes
for rs7021880 and its proxy SNPs.
Discussion
This study aimed to increase the understanding of the
relevance of four previously identified risk factors for the
severity of joint destruction in RA. To this end, 2,493
RA patients (and 5,895 sets of radiographs) included in
six independent cohorts from different parts of Europe
and North America were studied. In contrast to previous
observations in smaller studies, the variants in IL-6, IL-
10 and FCRL3 were not associated with radiographic
progression. This indicates that these variants do not
mediate the severity of structural damage in RA. A sta-
tistically significant association, confined to the ACPA-
negative subgroup of RA was found for rs2900180 in
C5-TRAF1. Fine-mapping of this region revealed the
lowest P-value for rs7021880 in TRAF1, although this
signal was not independent of other variants in this
region. The putative relevance of rs7021880 and its sur-
rounding region was supported by differences in RNAexpression of TRAF1 in peripheral blood and monocytes
in relation to these genotypes.
We have strongly considered whether the findings on
the C5-TRAF1 region may be false positive. However, des-
pite the fact that all replication cohorts individually had
less power than our first cohort and it was unlikely to find
statistically significant results in the individual replication
cohorts, the obtained effect sizes and directionalities were
similar in the Umeå, HCSC-RAC and NDB cohorts. Also,
the meta-analysis on these cohorts was highly significant
(P= 6.35 × 10−8 for rs7021880). Therefore, in our view, it is
more likely that the finding on C5-TRAF1 in ACPA-negative
RA is a true positive finding than a false positive finding.
The association of rs2900180 in C5-TRAF1 with radio-
graphic progression was previously observed in two studies
on the total RA population [8,9]. The first study concerned
761 RA patients of the Norfolk Arthritis Register (NOAR)
with a radiograph after one or five years; 61% of these
patients were ACPA-negative. In ACPA-stratified analyses
after one year follow-up the effect was significant in
ACPA-negative RA-patients but not in ACPA-positive RA
patients. The second study reevaluated the NOAR with
longitudinal radiographs and also included patients of the
Early Rheumatoid Arthritis Study (ERAS); ACPA status
was not reported here [9]. The difference in findings in the
UK cohorts and our cohorts with regard to ACPA might
be the consequence of different frequencies of ACPA-
negativity between the cohorts. In the NOAR, the propor-
tion of ACPA-negative patients was higher than in our
cohorts (61% versus 28% of the total study population of
the six cohorts) [8]. Therefore, the ACPA-negative patients
may have contributed more to the results obtained for the
NOAR total RA population than in the total RA popula-
tions studied here. The consistency of the directionality of
the effect (the minor allele associated with more severe
damage) in the cohorts studied in the present study and
the previously studied cohorts of NOAR and ERAS
supported the validity of our findings.
Fine-mapping was performed to explore the C5-
TRAF1 region comprising rs2900180 which is located on
chromosome 9 and intergenic between C5 and TRAF1.
The threshold for significance of the fine-mapping ana-
lyses was corrected for 424 tests which is quite restrict-
ive as the markers included in the analyses are not
independent. However, this threshold decreased the
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had a P-value below this threshold. These variants were all
highly correlated and located in a 66 Kb region covering
TRAF1 and downstream extending to the C5-TRAF1 inter-
genic region and upstream to the TRAF1- PHF19 inter-
genic region. Also, these 66 Kb are located within a larger
region with a high LD spanning from C5 to PHF19 (based
on Ceu HapMap data and as described previously [28]). In
a conditional analysis including both the initial (rs2900180)
and the strongest associating variant (rs7021880), we could
not distinguish which variant is the most important.
Therefore, the conclusion is that the region encompassing
rs7021880 and rs2900180 is associated with radiographic
progression. Larger fine-mapping studies are required to
conclude definitely on the extent of the region that
presumably contains the causal variant.
Previously, we reported that rs10818488, which is also
located in the C5-TRAF1 region (intergenic C5-TRAF1),
was not associated with radiographic progression in 2,666
RA patients belonging to seven cohorts. No stratification
for ACPA was done for this analysis [29]. Also, when
rs18018488 was analyzed in the total RA population of the
present study which included four cohorts that were stud-
ied previously and two additional cohorts, no significant
associations were obtained (data not shown). In the
present study, rs10818488 was also included in the fine-
mapping data of the ACPA-negative patients and did
not pass the threshold for multiple testing (which was
P <1.18 × 10−4; the P-value for rs10818488 was 6.21 × 10−4)
(Figure 3C). To explore the relation between rs10818488
and rs2900180 genotypes, the genotypes were compared
(Table 2), showing incomplete correlations which is in line
with the R2 of 0.668 between these two variants. For
instance, all patients with genotype AA for rs2900180 had
genotype AA for rs10818488, but also other patients had
genotype AA for rs18018488. In total, 41 of the 276 ACPA-
negative patients (14.9%) had different genotypes which
explains the difference in the obtained P-values for
rs10818488 and rs2900180. The minor allele of rs2900180
that associated in the present study with a higher rate ofTable 2 Genotypes of rs10818488 and rs2900180 in the
ACPA-negative Leiden EAC patients
rs2900180 (A) Total
GG AG AA
rs10818488 (A) GG 88 0 0 88
AG 22 113 0 135
AA 2 17 34 53
Total 112 130 34 276
Presented are the frequencies of the genotypes for rs2900180 (A) and
rs10818488 (A) in the 276 ACPA-negative RA patients of the Leiden EAC. The
R2 between these variants was 0.668. Minor allele frequencies within this
group were 35.9% and 43.7% for rs2900180 and rs10818488, respectively.
ACPA, anti-citrullinated peptide antibodies; EAC, Early Arthritis Clinic.joint destruction in ACPA-negative RA is also associated
with a higher risk of RA [18,28]. Rs2900180 was observed
to associate with susceptibility to RA in both Caucasian
and Korean patients, in contrast to rs10818488, which was
observed to be a risk factor for RA only in Caucasian pa-
tients [30]. Hence, apparently not only the association with
RA-severity but also the associations with RA-susceptibility
are slightly different for rs2900180 and rs10818488.
A correlation of rs7021880 located in TRAF1 with
TRAF1 expression was observed in whole blood, although
rs7021880 was not the strongest associating genetic vari-
ant with TRAF1 expression [22]. These data are valuable
but reflect on a mixture of cells and constitutive expres-
sion. Interestingly, very recently two studies evaluated
eQTL effects on RNA expression of monocytes or den-
dritic cells derived from monocytes after several stimuli
(response eQTL). These data are attractive since mono-
cytes play a relevant role in the development and progres-
sion of RA and because it is conceivable to suggest that
variants that associate with progression of the disease are
expressed in response to inflammatory stimuli. Hence, dif-
ferences in such expression may affect the disease course.
The expression of TRAF1 in monocytes was significantly
altered after LPS-stimulation compared to naïve mono-
cytes and rs7021880 genotypes were associated with this
change in expression after stimulation [25]. Genetic vari-
ants might thus affect the level of TRAF1 expression in
response to stimulation. Similar findings were observed in
dendritic cells derived from monocytes for rs881375, a
good proxy of rs7021880 (R2 = 0.902) [26]. TRAF1 is
involved in the NF-ĸB pathway, providing a potential
pathway for how these genetic variants may influence pro-
gression of joint destruction. The analyses on the large
bioinformatics databases supported the notion that the
region surrounding rs7021880 has a regulatory function in
monocytes, but these databases did not allow us to per-
form conditional analyses on the genetic variants in this
region in relation to RNA expression to identify independ-
ent effects. In addition, in several of the studies explored
the directionality of the effects on expression was not
clearly presented, hampering the interpretation of the
potential effects of rs7021880. Although most studies
reported on the expression of TRAF1, eQTL effects on C5
in certain cell types have also been reported. The data
available do not allow us to conclude whether effects
on expression are consistent across cell types. More
studies are needed to explain how the C5-TRAF1
region is relevant for radiographic progression in
ACPA-negative RA.
The variants in IL-6, IL-10 and FCRL3 were not associ-
ated with radiographic progression. Also, the directions
of the effects between the different cohorts were diverse
and no tendency for association was observed. The ini-
tial findings on these variants were obtained in studies
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present study.
This study was started in response to findings of a re-
cent review of the literature on genetic variants that are
associated with radiographic progression in RA [22].
Although genotyping data of five of the cohorts were
retrieved from the Immunochip, we did not intend to
analyze the whole Immunochip, as this was done re-
cently in a study that included three of the six studies
that are examined in the present study [20]. This study
was focused on the variants for which existing data
were contradictory and we went into detail by also per-
forming analyses stratified for ACPA. The total number
of genetic variants for radiographic progression that are
identified and either replicated in independent cohort
studies or found significant in meta-analysis is now
thirteen (including C5-TRAF1) of which nine were
identified in the total RA population (summarized in
Table 3). The ACPA-negative subgroup was studied
separately in only five studies (excluding the present
study). Of these, rs8192916 in GRZB and rs1485305
in OPG were reported to have a statistically significantTable 3 Overview of genetic variants for radiographic progre
significant in meta-analysis
Severity variant (risk allele) Located in/nearby gene(s) (chromosom
SE [31] HLA-DRB1 (chr 6)
rs4810485 (T) [32] CD40 (chr 20)




rs1896368 (G) [34] DKK-1 (chr 10)
rs1896367 (G) [34]
rs1528873 (A) [34]
rs2104286 (T) [35] IL2RA (chr 10)
rs8192916 (A) [36] GRZB (chr 14)
rs1119132 (A) [37] IL4R (chr 16)
rs7607479 (T) [38] SPAG16 (chr 2)
rs26232 (C) [39] C5orf30 (chr 5)
rs11908352 (A) [20] MMP-9 (chr 20)
rs451066 (A) [20] rs1465788 (chr 14)
rs1485305 (T) [40] OPG (chr 8)
rs2900180 (A) C5-TRAF1 (chr 9)
aAfter adjustment for ACPA, comparable effect sizes were observed (data not shown);
subgroups (ACPA-negative beta = 1.05 and P = 1.98 × 10−3; ACPA-positive beta = 1.03 a
observed in both subgroups (data not shown); dafter adjustment for ACPA and RF a sig
ACPA, the effect size was larger in the ACPA-positive than in the ACPA-negative subgro
the analyses resulted in significant P-values; fafter stratification for ACPA, almost similar
number of patients per subgroup, none of the analyses resulted in significant P-values
patients (beta = 1.29, P = 0.001) but not in ACPA-positive patients, although a similar tr
association remained significant (beta = 1.20, P = 0.02). ACPA, anti-citrullinated peptide
metalloproteinase; NA, not applicable; RA, rheumatoid arthritis.association with radiographic progression within the
ACPA-negative subgroup; for the other three variants
(rs1119132 in IL4R, rs11908352 in MMP-9 and rs451066
on chromosome 14) similarity in effect sizes were
reported but statistical significance was not obtained
which may be due to smaller sample sizes. The data
in Table 3 and the present data show that genetic
risk factors for radiographic progression in ACPA-
positive and ACPA-negative RA are not similar and
further support the notion of two separate disease
subsets of RA.
Conclusions
In conclusion, in contrast to initial reports, variants in IL-
6, IL-10 and FCRL3 are not associated with radio-
graphic progression. The association between rs2900180
in C5-TRAF1 and radiographic progression is con-
fined to ACPA-negative RA. A region surrounding
rs2900180 affects TRAF1 expression in whole blood
and monocytes. Further functional studies are needed
to elucidate the underlying biological mechanisms in
more detail.ssion that are replicated in independent cohorts or found
e) Risk population Functional associations
All RA Associated with ACPA-presence
ACPA-pos NA
All RAa NA
All RA Serum level DKK-1
All RA Serum level IL2Rα
All RAb RNA expression in whole blood (eQTL)
All RAc NA
ACPA-pos Serum level MMP-3
All RAd NA
All RAe Serum level MMP-9
All RAf NA
All RAg NA
ACPA-neg RNA expression whole blood and monocytes
bafter stratification for ACPA, significant associations were observed in both
nd P = 5.40 × 10−2); cafter stratification for ACPA, comparable effect sizes were
nificant association was observed (beta = 0.90, P = 0.03); eafter stratification for
up. However, considering the small number of patients per subgroup, none of
effect sizes were observed in both subgroups. However, considering the small
; gafter stratification, a significant association was observed in ACPA-negative
end was observed (beta = 1.14, P = 0.11). After adjustment for ACPA and RF the
antibodies; eQTL, expression quantitative trait locus; MMP, matrix
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Additional file 1: Distribution of residuals of the used models for
each dataset individually. Presented are histograms of the residuals for
the analyses of radiographic progression for each dataset individually.
Radiographic scores for all datasets were log-transformed. For the
analyses in the cohorts with multiple radiographs per patient (Leiden
EAC, Umeå, Madrid and Wichita) a multivariate normal regression analysis
was used. For the datasets with one radiograph per patient (NARAC and
NDB), the estimated yearly progression rate was studied by linear regression
analysis. All residuals approximate a normal distribution, indicating an
appropriate fit of the models.
Additional file 2: Genetic variants in IL-6 (A), IL-10 (B), C5-TRAF1 (C)
and FCRL3 (D) in relation to radiographic joint damage progression
in ACPA-negative and ACPA-positive subgroups. Yearly radiographic
progression rates per individual cohort and the meta-analyses evaluating
the cohorts with ACPA-negative and ACPA-positive patients separately.
Analysis on the ACPA-negative subgroup of the Wichita cohort was not
performed as it included only three ACPA-negative patients. Presented
are the fixed effect P-values. Rs1800795 (IL-6) ACPA-negative: I2 0.0%,
P = 0.91; P fixed effect = 0.63, P random effect = 0.63. Rs1800795 (IL-6)
ACPA-positive: I2 0.0%, P = 0.53; P fixed effect = 0.60. P random effect =
0.60. Rs1800896 (IL-10) ACPA-negative: I2 4.3%, P = 0.37; P fixed effect =
0.99, P random effect = 0.88. Rs1800896 (IL-10) ACPA-positive: I2 0.0%,
P = 0.48; P fixed effect = 0.99, P random effect = 0.99. Rs2900180 (C5-TRAF1)
ACPA-negative: I2 33.0%, P = 0.22; P fixed effect = 5.85 × 10−7, P random
effect = 0.0024. Rs2900180 (C5-TRAF1) ACPA-positive: I2 0.0%, P = 0.54; P fixed
effect = 0.13, P random effect = 0.13. Rs7528684 (FRCL3) ACPA-negative: I2
40.4%. P = 0.17; P fixed effect = 0.91, P random effect = 0.56. Rs7528684
(FRCL3) ACPA-positive: I2 7.4%. P = 0.37; P fixed effect = 0.91, P random
effect = 0.95.
Additional file 3: Results of the association with radiographic
progression of fine-mapped data from Chr 9:122,656 Kb-122,927Kb
in ACPA-negative Leiden EAC-patients.
Additional file 4: Fine-mapping analysis of 423 variants in the
ACPA-negative patients of the EAC conditioned on rs7021880.
Presented are the P-values of the multivariate normal regression
analyses of 423 variants in the C5-TRAF1 region in the ACPA-negative
patients of the EAC when conditioned on the strongest associating
variant (rs7021880). Using the Bonferroni correction (considering 423
variants studied) the cut-off for statistical significance was set at 1.18 × 10−4
as represented by the horizontal line.
Additional file 5: Rs7021880 in TRAF1 in relation to radiographic
joint damage progression in ACPA-negative RA patients. Fine-mapping
of the C5-TRAF1 region within the ACPA-negative patients of the Leiden
EAC revealed the lowest P-value for rs7021880 (TRAF1) (beta = 1.05,
P = 1.39 × 10−6). Presented are the yearly radiographic progression rates
for genotype rs7021880 per individual cohort and the meta-analysis
evaluating all cohorts with ACPA-negative patients. Analysis on the
ACPA-negative subgroup of the Wichita cohort was not performed as it
included only three ACPA-negative patients. Presented are the fixed
effect P-values. I2 22.9%, P = 0.27; P fixed effect = 6.35 × 10−8, P random
effect = 0.0012.
Additional file 6: Significant correlations of rs7021880 with RNA
cis-expression Quantitative Trait Loci (eQTL) in peripheral blood
in Westra et al. [22]. These data have been derived from the blood
eQTL browser that accompanies the manuscript of Westra et al. [22].
Expression Quantitative Trait Loci (eQTLs) were deemed cis-eQTLS when
the distance between the SNP position and the probe midpoint was
less than 250 Kb, whereas eQTLs with a distance greater than 5 Mb were
defined as trans-eQTLS. No trans-eQTLs were reported for rs7021880.
eQTL association tests were performed using a Spearman’s rank
correlation. Correlations were converted to Z-scores. If the Z-score is
negative, the minor allele is negatively correlated with expression.
Correction for multiple testing was performed by controlling the
‘probe-level’ false discovery rate at 0.05 permuting the gene expression
data 10 times resulting in significance thresholds for cis-eQTLs of 1.31 × 10−4
and for trans-eQTLs of 5.10 × 10−7 [22].Additional file 7: Significant associations of rs7021880 with RNA
cis-expression Quantitative Trait Loci (eQTL) in monocytes after two
hours stimulation with lipopolysaccharide in Fairfax et al. [25]. These
data have been derived from Additional file 6 of the article of Fairfax et al.
[25] Cis- and trans-acting expression Quantitative Trait Loci (eQTLs) were
defined as SNPs showing association with gene expression that were
located respectively within a 1 Mb and outside a 1 Mb region of the
associated probe. No trans-eQTLs were reported for rs7021880. If the t-stat is
negative, the minor allele is negatively correlated with expression. Correction
for multiple testing was performed by controlling the false discovery rate at
0.05 [25].
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